Sharmeen Mahmood
Hematology & Oncology · Newport Beach, CANPI 1639603236
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.7%), consulting fees and grants — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Daiichi Sankyo Inc. at 36.3% of the total. 2025 is the largest year on record at $918, 7.3 times the $125 reported in 2022. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 26 payments — averaging $92.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$874
- Exelixis Inc.$529
- AstraZeneca$350
- Regeneron Healthcare Solutions, Inc.$125
- AVEO Pharmaceuticals, Inc.$91
- Tersera Therapeutics LLC$60
- plus $380 from 12 others
What the payments were for
- Consulting fees$65027%
- Grants$35015%
- Food & beverage$1,31855%
- Education$914%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 5 | $874 |
| Exelixis Inc. | 1 | $529 |
| AstraZeneca | 1 | $350 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| AVEO Pharmaceuticals, Inc. | 1 | $91 |
| Tersera Therapeutics LLC | 2 | $60 |
| Myriad Genetic Laboratories, Inc. | 1 | $51 |
| Genentech USA, Inc. | 2 | $48 |
| Taiho Oncology, Inc. | 2 | $46 |
| Puma Biotechnology, Inc. | 2 | $41 |
| Bayer | 1 | $32 |
| Deciphera Pharmaceuticals Inc. | 1 | $29 |
| Gilead | 1 | $28 |
| Novartis | 1 | $24 |
| AbbVie | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Eisai Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,409 in reported general payments places this provider in the 45th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 15 | $224,563 |
| EliquisApixaban | 46 | $31,213 |
| Anastrozole | 196 | $3,546 |
| Tamoxifen Citrate | 73 | $1,030 |
| Letrozole | 41 | $808 |
| Dexamethasone | 22 | $208 |
| Prochlorperazine Maleate | 26 | $181 |
| Duloxetine Hcl | 15 | $107 |
| Gabapentin | 34 | $101 |
| Alendronate Sodium | 27 | $95 |
| Ondansetron Hcl | 20 | $94 |
| Omeprazole | 11 | $63 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Newport Beach
- Misagh KarimiNewport Beach$782K
- Andrea StebelNewport Beach$486K
- George SemeniukNewport Beach$483K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.